Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy

Umar Farooq, Matthew J. Maurer, Carrie A Thompson, Gita Thanarajasingam, David J. Inwards, Ivana Micallef, William Macon, Sergei Syrbu, Tasha Lin, Yi Lin, Stephen Maxted Ansell, Grzegorz S Nowakowski, Thomas Matthew Habermann, James R Cerhan, Brian K. Link

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

This study aimed to describe the patterns of care and outcomes of diffuse large B cell lymphoma (DLBCL) after failure of front line anthracycline-based immunochemotherapy (IC). Patients with newly diagnosed lymphoma were prospectively enrolled in Molecular Epidemiology Resource (MER) of the University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellzence. All DLBCL and primary mediastinal B-cell lymphoma (PMBL) patients treated with front-line anthracycline-based IC were followed for relapse. Patients with relapse on follow-up and subsequently retreated were included in this analysis. 1039 patients received anthracycline-based IC between 2002 and 2012, of which 244 relapsed and were subsequently retreated. Across all therapies, overall survival at 4 years (OS4) from relapse was 28% and 103 patients ultimately underwent autologous haematopoietic cell transplant (autoHCT) with OS4 from autoHCT of 51%. Patients relapsing after 12 months from initial diagnosis had OS4 of 47% but those with a transient or no response to initial therapy had OS4 of only 13%. Outcomes of relapsed or refractory DLBCL differ substantially when categorized by response to initial therapy, timing of relapse and opportunity to undergo autoHCT. The design and interpretation of uncontrolled trials should account for this heterogeneity in patients with relapsed DLBCL.

Original languageEnglish (US)
Pages (from-to)50-60
Number of pages11
JournalBritish Journal of Haematology
Volume179
Issue number1
DOIs
StatePublished - Oct 1 2017

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Anthracyclines
Recurrence
Survival
Transplants
Lymphoma
Molecular Epidemiology
B-Cell Lymphoma
Therapeutics
Research

Keywords

  • autologous transplant
  • chemotherapy refractory
  • diffuse large B cell lymphoma
  • relapsed DLBCL

ASJC Scopus subject areas

  • Hematology

Cite this

Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy. / Farooq, Umar; Maurer, Matthew J.; Thompson, Carrie A; Thanarajasingam, Gita; Inwards, David J.; Micallef, Ivana; Macon, William; Syrbu, Sergei; Lin, Tasha; Lin, Yi; Ansell, Stephen Maxted; Nowakowski, Grzegorz S; Habermann, Thomas Matthew; Cerhan, James R; Link, Brian K.

In: British Journal of Haematology, Vol. 179, No. 1, 01.10.2017, p. 50-60.

Research output: Contribution to journalArticle

@article{0df1e486f3da4ed59a7404daf8f08f08,
title = "Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy",
abstract = "This study aimed to describe the patterns of care and outcomes of diffuse large B cell lymphoma (DLBCL) after failure of front line anthracycline-based immunochemotherapy (IC). Patients with newly diagnosed lymphoma were prospectively enrolled in Molecular Epidemiology Resource (MER) of the University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellzence. All DLBCL and primary mediastinal B-cell lymphoma (PMBL) patients treated with front-line anthracycline-based IC were followed for relapse. Patients with relapse on follow-up and subsequently retreated were included in this analysis. 1039 patients received anthracycline-based IC between 2002 and 2012, of which 244 relapsed and were subsequently retreated. Across all therapies, overall survival at 4 years (OS4) from relapse was 28{\%} and 103 patients ultimately underwent autologous haematopoietic cell transplant (autoHCT) with OS4 from autoHCT of 51{\%}. Patients relapsing after 12 months from initial diagnosis had OS4 of 47{\%} but those with a transient or no response to initial therapy had OS4 of only 13{\%}. Outcomes of relapsed or refractory DLBCL differ substantially when categorized by response to initial therapy, timing of relapse and opportunity to undergo autoHCT. The design and interpretation of uncontrolled trials should account for this heterogeneity in patients with relapsed DLBCL.",
keywords = "autologous transplant, chemotherapy refractory, diffuse large B cell lymphoma, relapsed DLBCL",
author = "Umar Farooq and Maurer, {Matthew J.} and Thompson, {Carrie A} and Gita Thanarajasingam and Inwards, {David J.} and Ivana Micallef and William Macon and Sergei Syrbu and Tasha Lin and Yi Lin and Ansell, {Stephen Maxted} and Nowakowski, {Grzegorz S} and Habermann, {Thomas Matthew} and Cerhan, {James R} and Link, {Brian K.}",
year = "2017",
month = "10",
day = "1",
doi = "10.1111/bjh.14813",
language = "English (US)",
volume = "179",
pages = "50--60",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy

AU - Farooq, Umar

AU - Maurer, Matthew J.

AU - Thompson, Carrie A

AU - Thanarajasingam, Gita

AU - Inwards, David J.

AU - Micallef, Ivana

AU - Macon, William

AU - Syrbu, Sergei

AU - Lin, Tasha

AU - Lin, Yi

AU - Ansell, Stephen Maxted

AU - Nowakowski, Grzegorz S

AU - Habermann, Thomas Matthew

AU - Cerhan, James R

AU - Link, Brian K.

PY - 2017/10/1

Y1 - 2017/10/1

N2 - This study aimed to describe the patterns of care and outcomes of diffuse large B cell lymphoma (DLBCL) after failure of front line anthracycline-based immunochemotherapy (IC). Patients with newly diagnosed lymphoma were prospectively enrolled in Molecular Epidemiology Resource (MER) of the University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellzence. All DLBCL and primary mediastinal B-cell lymphoma (PMBL) patients treated with front-line anthracycline-based IC were followed for relapse. Patients with relapse on follow-up and subsequently retreated were included in this analysis. 1039 patients received anthracycline-based IC between 2002 and 2012, of which 244 relapsed and were subsequently retreated. Across all therapies, overall survival at 4 years (OS4) from relapse was 28% and 103 patients ultimately underwent autologous haematopoietic cell transplant (autoHCT) with OS4 from autoHCT of 51%. Patients relapsing after 12 months from initial diagnosis had OS4 of 47% but those with a transient or no response to initial therapy had OS4 of only 13%. Outcomes of relapsed or refractory DLBCL differ substantially when categorized by response to initial therapy, timing of relapse and opportunity to undergo autoHCT. The design and interpretation of uncontrolled trials should account for this heterogeneity in patients with relapsed DLBCL.

AB - This study aimed to describe the patterns of care and outcomes of diffuse large B cell lymphoma (DLBCL) after failure of front line anthracycline-based immunochemotherapy (IC). Patients with newly diagnosed lymphoma were prospectively enrolled in Molecular Epidemiology Resource (MER) of the University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellzence. All DLBCL and primary mediastinal B-cell lymphoma (PMBL) patients treated with front-line anthracycline-based IC were followed for relapse. Patients with relapse on follow-up and subsequently retreated were included in this analysis. 1039 patients received anthracycline-based IC between 2002 and 2012, of which 244 relapsed and were subsequently retreated. Across all therapies, overall survival at 4 years (OS4) from relapse was 28% and 103 patients ultimately underwent autologous haematopoietic cell transplant (autoHCT) with OS4 from autoHCT of 51%. Patients relapsing after 12 months from initial diagnosis had OS4 of 47% but those with a transient or no response to initial therapy had OS4 of only 13%. Outcomes of relapsed or refractory DLBCL differ substantially when categorized by response to initial therapy, timing of relapse and opportunity to undergo autoHCT. The design and interpretation of uncontrolled trials should account for this heterogeneity in patients with relapsed DLBCL.

KW - autologous transplant

KW - chemotherapy refractory

KW - diffuse large B cell lymphoma

KW - relapsed DLBCL

UR - http://www.scopus.com/inward/record.url?scp=85029795555&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029795555&partnerID=8YFLogxK

U2 - 10.1111/bjh.14813

DO - 10.1111/bjh.14813

M3 - Article

VL - 179

SP - 50

EP - 60

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 1

ER -